LNTH — Lantheus Holdings, Inc.

—
Nasdaq · Health Care · Life Sciences Tools & Services · CIK 1521036 ·
Last close
$99.74
Market Cap
$6.51B
52W High
$111.86
52W Low
$49.67
ADV30
1,135,640
Next earnings
2026-11-05

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 388,180,000 241,855,000 100,215,000 75,029,000 2,414,662,000 593,298,000 1,102,884,000
Mar 2026 377,333,000 230,922,000 81,326,000 118,417,000 2,346,587,000 498,582,000 1,134,299,000
Dec 2025 406,786,000 240,875,000 77,184,000 54,088,000 2,227,399,000 359,121,000 1,137,602,000
Sep 2025 384,014,000 222,366,000 43,615,000 27,771,000 2,276,400,000 382,006,000 1,157,194,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$412,802,000
Investing CF
$-307,015,000
Financing CF
$-207,070,000
CapEx
$-24,971,000
Dividends Paid
—
Buybacks
$-200,017,000
EPS Diluted TTM
$4.14
As of
2026-08-09

Balance + Analyst (yfinance extras)

Retained Earnings
$872,950,000
Inventory
$57,551,000
Receivables
$354,056,000
ST Investments
—
EBIT TTM
$382,783,000
Pretax Income TTM
$362,976,000
Interest Exp TTM
$19,807,000
Analysts
9

Yahoo Snapshot (yfinance, live)

Total Revenue
$1,556,312,960
EBITDA
$392,224,992
Free Cash Flow
$451,656,000
Enterprise Value
$6,575,215,104
Total Cash
$593,297,984
Total Debt
$624,958,016
Shares Out
65,299,875
Trailing EPS
$4.18
Book Value
$20.10
ROE
22.2%
ROA
8.4%
Div Yield
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 1,541,609,000 315,559,000 233,559,000 2,227,399,000 1,137,602,000 1,089,797,000 390,141,000
Dec 2024 1,533,910,000 448,564,000 312,442,000 1,980,340,000 892,329,000 1,088,011,000 544,750,000
Dec 2023 1,296,429,000 364,642,000 326,661,000 1,651,149,000 835,257,000 815,892,000 305,260,000
Dec 2022 935,061,000 36,195,000 28,067,000 1,321,258,000 874,111,000 447,147,000 281,781,000

TTM Snapshot

Revenues TTM
$82,630,000
NetIncome TTM
$8,211,000
OpCashFlow TTM
$0
Assets (Latest)
$439,831,000
Forward EPS
$6.38

Max Pain — expiry 2026-10-16

max pain strike: $75.00 · spot: $99.74 · call oi: 2,144 · put oi: 482
Expected Move to 2026-10-16: ±$1.95 (1.96%) — implied range $97.79 – $101.69 · ATM straddle on $100.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
ICLR ICON PLC $13.30B $172.33 —
CRL CHARLES RIVER LABORATORIES INTERNATIONAL, INC. $14.11B $292.84 —
NEOG NEOGEN CORP $3.00B $13.76 —
MEDP Medpace Holdings, Inc. $17.27B $618.88 —
CLDX Celldex Therapeutics, Inc. $2.44B $31.10 —

News headlines (Yahoo Finance, 1h cache)

Lantheus Announces First Patient Dosed in SPARROW Phase 2/3 Registrational Trial in Prostate Cancer
2026-09-28 12:00 · Yahoo
Lantheus Holdings (LNTH) Could Be 7% Undervalued On BRAVNETSA Approval
2026-09-26 18:10 · Yahoo
Lantheus Holdings (LNTH) Stock May Be 14% Undervalued On FDA Approval
2026-09-26 02:08 · Yahoo
3 Reasons LNTH is Risky and 1 Stock to Buy Instead
2026-09-23 13:57 · Yahoo
Lantheus Receives Final FDA Approval for BRAVNETSA™ (Lutetium Lu 177 Dotatate), the Only Radiopharmaceutical FDA has Determined to be Bioequivalent and Therapeutically Equivalent to LUTATHERA® for the
2026-09-22 12:00 · Yahoo
2 Small-Cap Stocks to Consider Right Now and 1 That Underwhelm
2026-09-11 23:55 · Yahoo
Curium acquisition of Lantheus backed by $5.375B of debt financing
2026-08-26 20:56 · Yahoo
Lantheus Announces FDA Approval of TAUKLARIFY™ (Florquinitau F 18 Injection), an F18-Labeled Tau PET Imaging Agent for Alzheimer’s Disease
2026-08-14 12:00 · Yahoo
Lantheus Reports Second Quarter 2026 Financial Results
2026-08-06 11:00 · Yahoo
1 Healthcare Stock Worth Your Attention and 2 We Question
2026-08-04 05:01 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.